1. |
Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol, 2018, 22(5): 738-748.
|
2. |
Wang YY, Pang LY, Ma SF, et al. Epilepsy may be the major risk factor of mental retardation in children with tuberous sclerosis: a retrospective cohort study. Epilepsy Behav, 2017, 77: 13-18.
|
3. |
Roach ES. Applying the lessons of tuberous sclerosis: the 2015 hower award lecture. Pediatr Neurol, 2016, 63: 6-22.
|
4. |
Yang G, Shi ZN, Meng Y, et al. Phenotypic and genotypic characterization of Chinese children diagnosed with tuberous sclerosis complex. Clin Genet, 2017, 91(5): 764-768.
|
5. |
van Eeghen AM, Black ME, Pulsifer MB, et al. Genotype and cognitive phenotype of patients with tuberous sclerosis complex. Eur J Hum Genet, 2012, 20(5): 510-515.
|
6. |
Saxena A, Sampson JR. Epilepsy in Tuberous sclerosis: phenotypes, mechanisms, and treatments. Semin Neurol, 2015, 35(3): 269-276.
|
7. |
Bolton PF, Clifford M, Tye C, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the Tuberous Sclerosis 2000 Study. Psychol Med, 2015, 45(11): 2321-2331.
|
8. |
Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol, 2015, 14(7): 733-745.
|
9. |
Welin KO, Carlqvist P, Svensson A, et al. Epilepsy in tuberous sclerosis patients in Sweden - healthcare utilization, treatment, morbidity, and mortality using national register data. Seizure, 2017, 53: 4-9.
|
10. |
Jeong A, Nakagawa JA, Wong M. Predictors of drug-resistant epilepsy in tuberous sclerosis complex. J Child Neurol, 2017, 32(14): 1092-1098.
|
11. |
Gül Mert G, Altunbaşak Ş, Hergüner Ö, et al. Factors affecting epilepsy prognosis in patients with tuberous sclerosis.Childs Nerv Syst, 2019, 35(3): 463-468.
|
12. |
Benova B, Petrak B, Kyncl M, et al. Early predictors of clinical and mental outcome in tuberous sclerosis complex: a prospective study. Eur J Paediatr Neurol, 2018, 22(4): 632-641.
|
13. |
Overwater IE, Verhaar BJ, Lingsma HF, et al. Interdependence of clinical factors predicting cognition in children with tuberous sclerosis complex. J Neurol, 2017, 264(1): 161-167.
|
14. |
Fohlen M, Taussig D, Ferrand-Sorbets S, et al. Refractory epilepsy in preschool children with tuberous sclerosis complex: early surgical treatment and outcome. Seizure, 2018, 60: 71-79.
|
15. |
Liang S, Li A, Zhao M, et al. Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology. Epilepsia, 2010, 51(11): 2316-2321.
|
16. |
Liang S, Zhang J, Yang Z, et al. Long-term outcomes of epilepsy surgery in tuberous sclerosis complex. J Neurol, 2017, 264(6): 1146-1154.
|
17. |
Gipson TT, Johnston MV. New insights into the pathogenesis and prevention of tuberous sclerosis-associated neuropsychiatric disorders (TAND). F1000Res, 2017, 6: F1000 Faculty Rev-859.
|
18. |
Wilde L, Eden K, de Vries P, et al. Self-injury and aggression in adults with tuberous sclerosis complex: frequency, associated person characteristics, and implications for assessment. Res Dev Disabil, 2017, 64: 119-130.
|
19. |
Northrup H, Krueger DA, International tuberous sclerosis complex consensus group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol, 2013, 49(4): 243-254.
|
20. |
Amin S, Lux A, Calder N, et al. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol, 2017, 59(6): 612-617.
|
21. |
Yang G, Yang L, Yang X, et al. Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: a systematic review and meta-analysis. Exp Ther Med, 2015, 9(2): 626-630.
|
22. |
Samueli S, Abraham K, Dressler A, et al. Efficacy and safety of Everolimus in children with TSC-associated epilepsy - Pilot data from an open single-center prospective study. Orphanet J Rare Dis, 2016, 11(1): 145.
|
23. |
Curatolo P, Franz DN, Lawson JA, et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health, 2018, 2(7): 495-504.
|
24. |
Muncy J, Butler IJ, Koenig MK. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol, 2009, 24(4): 477.
|
25. |
邹丽萍, 刘玉洁, 庞领玉, 等. 雷帕霉素治疗儿童结节性硬化症合并癫痫的临床效果及安全性观察. 中华儿科杂志, 2014, 52(11): 812-816.
|
26. |
Zou LP, Liu YT. Letter re: sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial. Neurology, 2017, 88(10): 1008.
|
27. |
Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology, 2016, 87(10): 1011-1018.
|
28. |
Krueger D, Wilfong A, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol, 2013, 74(5): 679-687.
|
29. |
Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology, 2016, 87(23): 2408-2415.
|
30. |
Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol, 2011, 15(5): 424-431.
|
31. |
Tibussek D, Klepper J, Korinthenberg R, et al. Treatment of infantile Spasms: report of the interdisciplinary guideline committee coordinated by the german-speaking society for neuropediatrics. Neuropediatrics, 2016, 47(3): 139-150.
|
32. |
Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol, 2010, 25(11): 1340-1347.
|
33. |
Jennesson M, van Eeghen AM, Caruso PA, et al. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res, 2013, 104(3): 269-274.
|
34. |
Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia, 2016, 57(10): 1617-1624.
|
35. |
Geffrey AL, Belt OD, Paolini JL, et al. Lacosamide use in the treatment of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res, 2015, 112: 72-75.
|
36. |
Kossoff EH, Thiele EA, Pfeifer HH, et al. Tuberous sclerosis complex and the ketogenic diet. Epilepsia, 2005, 46(10): 1684-1686.
|
37. |
Park S, Lee EJ, Eom S, et al. Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children. J Epilepsy Res, 2017, 7(1): 45-49.
|